Skip to main content
OpenTrials
Completed

NCT Number: NCT00996970

Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons

The purpose of this research is to determine the effectiveness of the novel H1Nl influenza (inactivated/killed formulation) vaccine among both HIV-infected and HIV-uninfected persons. The administration of the H1Nl vaccination is not part of the study's procedures, but is being given as part of routine care.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza Blood-Borne Infections Communicable Diseases Genital Diseases HIV Infections Immune System Diseases Immunologic Deficiency Syndromes Infections Influenza, Human Lentivirus Infections Orthomyxoviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Urogenital Diseases Virus Diseases

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Naval Medical Center San Diego, San Diego, California, United States

Loading trial locations.

About this study

The investigators study is being conducted to evaluate and compare the seroresponses of the novel H1N1 vaccination among HIV positive and negative persons receiving the novel H1N1 vaccination as part of routine clinical care, with secondary objectives examining the impact of prior seasonal vaccinations on subsequent seroresponse to the novel H1N1 vaccination, determining potential reactions (local or systemic) to this new vaccine among patients, and assessing for potential immunologic/virologic changes (in CD4/HIV RNA levels) after H1N1 vaccination among HIV patients. Finally, the investigators will collect data on influenza-like illnesses (ILI) and H1N1 events during the study follow-up period and influenza isolates causing ILI events will be genetically characterized.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-50 years of age
  • Receiving the novel H1N1 vaccine (killed formulation) as part of routine clinical care
  • A military beneficiary who expects to remain in the local area for the next 6 months

Exclusion criteria

  • Healthcare worker who is involved in direct patient care
  • Acute febrile illnesses within 30 days prior to H1N1 vaccination (e.g., pneumonia, influenza, ILI)
  • Diabetes type 1 or type 2
  • Systemic steroid or immunosuppressive medication use within 4 weeks of vaccination
  • Active diagnoses of a cancer (non-melanoma skin cancer allowed).
  • History of organ transplant
  • Chronic active hepatitis B or C
  • Active illicit drug use or alcohol abuse
  • Blood transfusion within the last year
  • Allergy to eggs
  • Previous significant adverse reaction (e.g., anaphylaxis) to the seasonal influenza vaccination
  • History of serious reactions to any prior vaccination (e.g., Guillain Barre Syndrome (GBS)).
  • Received another vaccination in the last 4 weeks (receipt of seasonal influenza vaccination is allowed)
  • Among females of childbearing potential, pregnant or within 6 weeks of being postpartum
  • History of ILI which was confirmed as an H1N1 infection

Treatment and study plan

Primary outcomes

  1. To compare the immunogenicity via anti-hemagglutinin responses following H1N1 vaccination between HIV positive and negative persons.

    Time frame: interim = 2 months; 6 month f/u = 8 months

Secondary outcomes

  1. To compare the immunogenicity via HAI titer levels, microneutralization seroresponses and titer levels, and cellular responses following H1N1 vaccination between HIV positive and negative persons.

    Time frame: 1 year

  2. Among those undergoing vaccination with the seasonal influenza vaccine during the current influenza season, to compare the presence of a positive seroresponse between HIV positive and negative persons

    Time frame: 1 year

  3. To evaluate the effect of pre-existing anti-influenza immunity and recent history of seasonal influenza vaccination on seroresponses to the H1N1 influenza vaccine among both HIV positive and negative persons.

    Time frame: 1 year

  4. To compare the durability of the H1N1 immunologic responses at 6 months post-vaccination between HIV-infected and uninfected persons.

    Time frame: 1 year

  5. To evaluate the number of ILIs and documented influenza cases among HIV-infected and uninfected persons after initial vaccination, and to genetically characterize the influenza strains causing ILI events in our study cohort.

    Time frame: 1 year

  6. To evaluate the impact of CD4 counts/percentages, HIV RNA levels, and HAART use on the immunologic responses to H1N1 vaccination in HIV positive subjects.

    Time frame: 1 year

  7. To evaluate the impact of the H1N1 vaccine on CD4 counts/percentages and HIV RNA levels in HIV positive subjects.

    Time frame: 2 months

  8. To evaluate potential adverse reactions of the H1N1 vaccine in HIV positive versus negative subjects.

    Time frame: 2 months

Sponsors and collaborators

Lead sponsor

Henry M. Jackson Foundation for the Advancement of Military Medicine

Other

Collaborators

  • Infectious Diseases Clinical Research Program
  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Important dates

Study start
2009
Primary completion
2009
Study completion
2022
First posted
Oct 16, 2009
Registry last updated
Mar 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.